Christophe Arbet-Engels, MD, Chief Medical Officer
Clinical trials targeting these pathways have produced largely disappointing results
For many clients, the appeal is simple: quick treatment, no major downtime, and a focused approach to metabolic support
Similarly, the impact of renal or hepatic impairment on BPC-157 pharmacokinetics remains unexplored, though the peptide's metabolism to amino acids and apparent wide therapeutic window suggest limited risk even with reduced clearance
Notably, BPC 157 may scavenge reactive oxygen species due to its structure: it contains four carboxylic groups, and when they are reactivated (by glutathione or enzymes), the antioxidant activity is very high
Symptom overlap with semaglutide side effects Semaglutide can cause dizziness and general malaise, which can mask the subtle early signs of UTI